A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR Amyloidosis
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Patisiran (Primary)
- Indications Amyloid polyneuropathy; Transthyretin-related hereditary amyloidosis
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 27 Nov 2019 Results assessing pharmacokinetics of Patisiran in Patients With Hereditary Transthyretin-Mediated Amyloidosis published in the Journal of Clinical Pharmacology
- 21 Mar 2014 Results from a further analyses of trial data will be presented at the XIVth International Symposium on Amyloidosis (ISA) according to an Alnylam Pharmaceuticals media release.
- 22 Nov 2013 New trial record